Ascendis Pharma A/S (ASND) Fundamental Analysis: Bull vs. Bear Case

ASND

Ascendis Pharma A/S

Fundamental data last updated:June 5, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

DK

Next Earnings Date

08/06/2026

Business Summary

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

VALUATION

P/E

27.03 Market Cap ($M USD)

$13.72B

Forward P/E

10.72 PEG

0.07 PRICE TO SALES

13.54 PRICE TO BOOK

24.01 EV / EBITDA

-1738.78

5-Year Average P/E

Free Cash Flow Yield

0.36%

DCF Value

$-5111.80

Graham Number

$38.26

Price to FCF

278.99 EV to FCF

286.69 Earnings Yield

4.32%

FCF Yield

0.36%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$8.21

Next Year EPS Growth Estimate

$20.72

Next Year Revenue Growth Estimate

$337.99B

Return on Equity (ROE)

-5641.90%

FREE CASH FLOW

Operating Margin

-0.80%

Debt-to-Equity

-5.35

Piotroski F-Score

5 Altman Z-Score

3.96 Return on Invested Capital (ROIC)

-0.79%

Current Ratio

1.00 Quick Ratio

0.72 Net Debt to EBITDA

-46.69

Interest Coverage

-0.04

Gross Profit margin

88.17%

FCF PER SHARE

$0.68

REVENUE PER SHARE

$14.06

Gainseekers Quantitative Analysis

Summary

The market seems to have mispriced Ascendis Pharma A/S, with its snapshot price trading significantly above its DCF value. The Forward P/E of 11.46 suggests potential growth, yet the staggering negative ROE of -5641.90% raises red flags about management’s efficiency. Despite a solid Altman Z-score of 3.85 indicating financial stability, the earnings yield of 4.05% is modest, hinting at limited immediate returns. The Graham Number further underscores overvaluation concerns, suggesting caution for deep value investors.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, Ascendis Pharma is well-positioned to leverage AI advancements for drug discovery and personalized medicine. The industry's inherent reliance on cutting-edge technology provides a natural resilience to tech shifts. As AI continues to evolve, the company could enhance its R&D efficiency and speed to market.

The Bull Case

For the discerning GARP investor, Ascendis Pharma offers intriguing potential. The Forward PEG ratio of 0.075 is a beacon of undervaluation, suggesting growth at a reasonable price. A Piotroski F-Score of 5 indicates moderate financial health, while the gross profit margin of 88.17% reflects strong pricing power. Despite a low FCF yield, the company's ability to innovate could drive future capital efficiency.

The Bear Case

Ascendis Pharma's structural weaknesses are glaring. The Price/Book ratio of 25.63 and Price/Sales of 14.45 signal an overvalued stock, especially when juxtaposed with its negative operating margin. The company is technically overextended, trading just 5.06% below its 52-week high, which could limit upside potential. Additionally, the negative EV to EBITDA ratio highlights severe profitability issues, casting doubt on its operational viability.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$287.50

Institutional Ownership %

1-Year Beta

0.41 Insider Buying % (6 Mo)

Distance to 52-Week High

12.93%

Distance to 52-Week Low

27.55%

EARNINGS SURPRISE %

52.38%

50-DAY SMA

$233.07

200-DAY SMA

$215.98

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.